Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
13 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: Global Manufacturing & Supply
Global Manufacturing & Supply Kasper Bødker Mejlvang CMD26 EVP, Global Manufacturing & Supply Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 Global Manufacturing & Supply Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown,
Slide 3: Significant expansion of production footprint will deliver on commercial opportunities and pipeline acceleration
3 Global Manufacturing & Supply Significant expansion of production footprint will deliver on commercial opportunities and pipeline acceleration Top 5 CAPEX investments Kalundborg, DK Clayton, US Hillerød, DK Chartres, FR Montes Claros, BR 59 bDKK 40 bDKK 19 bDKK 17 bDKK 8 bDKK (~9 bUSD) (~6 bUSD) (
Slide 4: Manufacturing strategy focuses on flexible, scalable, and cost competitive production
4 Global Manufacturing & Supply Manufacturing strategy focuses on flexible, scalable, and cost competitive production Fierce competition Consumer-like Complex pipeline Supply resilience expectations Shorter lead times and More variants, channels More modalities, devices Flexible capacity across laun
Slide 5: Novo’s manufacturing capabilities provide a competitive advantage
5 Global Manufacturing & Supply Novo’s manufacturing capabilities provide a competitive advantage Decades of expertise in large-scale manufacturing World-leading scale in insulin and GLP-1 manufacturing Large yeast-based production network with significant Million patients on Novo products in first
Slide 6: Manufacturing setup enables faster development decisions and shorter time to market
6 Global Manufacturing & Supply Manufacturing setup enables faster development decisions and shorter time to market Accelerating innovation Enabling commercial success R&D sets the Faster Manufacturing Wegovy® pill US launch fastest ever target development delivers 14 days from approval to launch Ac
Slide 7: High-volume platforms provide flexibility and ample capacity to meet future demand
7 Global Manufacturing & Supply High-volume platforms provide flexibility and ample capacity to meet future demand Flexible device and presentation platforms support a more Multiple manufacturing platforms to support R&D and enable consumer-driven market commercial launches across therapeutic areas
Slide 8: Manufacturing network is fit for future demand
8 Global Manufacturing & Supply Manufacturing network is fit for future demand 7 Denmark, 6 sites Ireland API, fill, finish and tablet API sites Tablet Belgium Fill and finish 11 France United States, 5 sites Fill and finish API, fill, finish and tablet Fill and finish sites China Italy Fill and fin
Slide 9: A significant commitment to US patients, people and the future
9 Global Manufacturing & Supply A significant commitment to US patients, people and the future Novo US manufacturing Strong commitment to the US Five manufacturing sites across the US USD billions 5 manufacturing sites 12 bUSD committed New Hampshire 12 Bloomington Petersburg 10 bUSD invested Durham
Slide 10: Clear roadmap to scale oral capacity to meet market demand
10 Global Manufacturing & Supply Clear roadmap to scale oral capacity to meet market demand Roadmap to scale oral capacity Significant scaling towards 2030 expected 1. Scaling API production 2. Scaling tabletting 3. Cost competitiveness ~1.5 million Experience in Måløv ✓ CAPEX invested ✓ New oral fo
Slide 11: Renewed focus on productivity to sustain cost competitiveness
11 Global Manufacturing & Supply Renewed focus on productivity to sustain cost competitiveness Ambition to keep adjusted gross margin Continuous focus on lowering unit cost Optimised Wegovy® pill COGS broadly stable and improving productivity DKK billions ILLUSTRATIVE ILLUSTRATIVE API optimisation D
Slide 12: Strong foundation for future growth and value creation
12 Global Manufacturing & Supply Strong foundation for future growth and value creation From capacity build-out to network CAPEX-to-sales ratio expected to decline GMS supports both Novo’s R&D and optimisation and value creation towards industry average commercial efforts DKK billion ILLUSTRATIVE Bu
Slide 13: Novo has significantly expanded manufacturing capacity, laying the foundation to support future demand
13 Global Manufacturing & Supply 1 2 3 Novo has significantly expanded Novo is now shifting its focus from With a renewed focus on cost manufacturing capacity, laying the CAPEX investments toward margins, competitiveness, Novo has an ambition foundation to support future demand in enhancing producti